Last reviewed · How we verify
Hormone refractory prostate cancer
Approved treatments
- Zejula · GSK
Zejula works by blocking the action of an enzyme called PARP, which helps repair damaged DNA in cancer cells. - Lynparza · University of Texas Southwestern Medical Center
- Lynparza · AstraZeneca
Lynparza blocks the repair of DNA damage in cancer cells by inhibiting the enzyme PARP. - Nubeqa · Bayer
Darolutamide inhibits androgen receptor activity, reducing prostate cancer cell growth and tumor size.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Hormone refractory prostate cancer patent landscape — cliff calendar, originator estates, attackable patents
- Hormone refractory prostate cancer treatment landscape brief
- Hormone refractory prostate cancer treatment updates RSS
Frequently asked questions about Hormone refractory prostate cancer
What drugs treat Hormone refractory prostate cancer?
Tracked treatments include Zejula, Lynparza, Nubeqa.
What is the treatment for Hormone refractory prostate cancer?
Standard treatment for Hormone refractory prostate cancer includes Zejula, Lynparza, Nubeqa. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Hormone refractory prostate cancer patent cliff · Hormone refractory prostate cancer CI report
- Treatment: Zejula · GSK
- Treatment: Lynparza · University of Texas Southwestern Medical Center
- Treatment: Lynparza · AstraZeneca
- Treatment: Nubeqa · Bayer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing